Treatment  ||| S:0 E:10 ||| NN
of  ||| S:10 E:13 ||| IN
multiresistant  ||| S:13 E:28 ||| FW
Gram  ||| S:28 E:33 ||| FW
positive  ||| S:33 E:42 ||| FW
endocarditis  ||| S:42 E:55 ||| FW
Epidemiology  ||| S:55 E:68 ||| NNP
of  ||| S:68 E:71 ||| IN
infectious  ||| S:71 E:82 ||| JJ
endocarditis  ||| S:82 E:95 ||| NN
has  ||| S:95 E:99 ||| VBZ
changed  ||| S:99 E:107 ||| VBN
in  ||| S:107 E:110 ||| IN
last  ||| S:110 E:115 ||| JJ
decades ||| S:115 E:122 ||| NNS
,  ||| S:122 E:124 ||| ,
endocarditis  ||| S:124 E:137 ||| VBD
associated  ||| S:137 E:148 ||| VBN
to  ||| S:148 E:151 ||| TO
hospital  ||| S:151 E:160 ||| NN
practices ||| S:160 E:169 ||| NNS
,  ||| S:169 E:171 ||| ,
sustained  ||| S:171 E:181 ||| VBN
by  ||| S:181 E:184 ||| IN
multiresistant  ||| S:184 E:199 ||| JJ
pathogens  ||| S:199 E:209 ||| NNS
being  ||| S:209 E:215 ||| VBG
highly  ||| S:215 E:222 ||| RB
increased ||| S:222 E:231 ||| VBN
.  ||| S:231 E:233 ||| .
In  ||| S:233 E:236 ||| IN
particular ||| S:236 E:246 ||| JJ
,  ||| S:246 E:248 ||| ,
methicillin-resistant  ||| S:248 E:270 ||| JJ
staphylococci  ||| S:270 E:284 ||| NNS
( ||| S:284 E:285 ||| -LRB-
MRSA ||| S:285 E:289 ||| NNP
) ||| S:289 E:290 ||| -RRB-
,  ||| S:290 E:292 ||| ,
almost  ||| S:292 E:299 ||| RB
resistant  ||| S:299 E:309 ||| JJ
to  ||| S:309 E:312 ||| TO
a  ||| S:312 E:314 ||| DT
number  ||| S:314 E:321 ||| NN
of  ||| S:321 E:324 ||| IN
other  ||| S:324 E:330 ||| JJ
antimicrobial  ||| S:330 E:344 ||| JJ
classes ||| S:344 E:351 ||| NNS
,  ||| S:351 E:353 ||| ,
often  ||| S:353 E:359 ||| RB
exhibit  ||| S:359 E:367 ||| VB
a  ||| S:367 E:369 ||| DT
reduced  ||| S:369 E:377 ||| JJ
susceptibility  ||| S:377 E:392 ||| NN
to  ||| S:392 E:395 ||| TO
vancomycin  ||| S:395 E:406 ||| VB
( ||| S:406 E:407 ||| -LRB-
h-VISA ||| S:407 E:413 ||| NNP
)  ||| S:413 E:415 ||| -RRB-
with  ||| S:415 E:420 ||| IN
MICs ||| S:420 E:424 ||| NNP
'  ||| S:424 E:426 ||| POS
values  ||| S:426 E:433 ||| NNS
more  ||| S:433 E:438 ||| RBR
e  ||| S:438 E:440 ||| JJ
than  ||| S:440 E:445 ||| IN
1  ||| S:445 E:447 ||| CD
mg ||| S:447 E:449 ||| CD
/ ||| S:449 E:450 ||| CD
l ||| S:450 E:451 ||| NN
,  ||| S:451 E:453 ||| ,
leading  ||| S:453 E:461 ||| VBG
to  ||| S:461 E:464 ||| TO
suppose  ||| S:464 E:472 ||| VB
a  ||| S:472 E:474 ||| DT
reduced  ||| S:474 E:482 ||| JJ
therapeutic  ||| S:482 E:494 ||| JJ
efficacy  ||| S:494 E:503 ||| NN
of  ||| S:503 E:506 ||| IN
this  ||| S:506 E:511 ||| DT
drug ||| S:511 E:515 ||| NN
.  ||| S:515 E:517 ||| .
Thirty-one  ||| S:517 E:528 ||| JJ
percent  ||| S:528 E:536 ||| NN
of  ||| S:536 E:539 ||| IN
MRSA  ||| S:539 E:544 ||| NNP
strains  ||| S:544 E:552 ||| NNS
in  ||| S:552 E:555 ||| IN
the  ||| S:555 E:559 ||| DT
ICE  ||| S:559 E:563 ||| NNP
study ||| S:563 E:568 ||| NN
,  ||| S:568 E:570 ||| ,
which  ||| S:570 E:576 ||| WDT
prospectively  ||| S:576 E:590 ||| RB
collected  ||| S:590 E:600 ||| VBN
more  ||| S:600 E:605 ||| JJR
than  ||| S:605 E:610 ||| IN
5000  ||| S:610 E:615 ||| CD
endocarditis ||| S:615 E:627 ||| NN
,  ||| S:627 E:629 ||| ,
were  ||| S:629 E:634 ||| VBD
h-VISA ||| S:634 E:640 ||| JJ
.  ||| S:640 E:642 ||| .
Daptomycin  ||| S:642 E:653 ||| NNP
shows  ||| S:653 E:659 ||| VBZ
a  ||| S:659 E:661 ||| DT
rapid  ||| S:661 E:667 ||| JJ
bactericidal  ||| S:667 E:680 ||| JJ
activity  ||| S:680 E:689 ||| NN
against  ||| S:689 E:697 ||| IN
both  ||| S:697 E:702 ||| DT
methicillin-susceptible  ||| S:702 E:726 ||| JJ
staphylococcci  ||| S:726 E:741 ||| NNS
( ||| S:741 E:742 ||| -LRB-
MSSA ||| S:742 E:746 ||| NNP
)  ||| S:746 E:748 ||| -RRB-
and  ||| S:748 E:752 ||| CC
MRSA ||| S:752 E:756 ||| NNP
,  ||| S:756 E:758 ||| ,
included  ||| S:758 E:767 ||| VBD
those  ||| S:767 E:773 ||| DT
strains  ||| S:773 E:781 ||| NNS
with  ||| S:781 E:786 ||| IN
reduced  ||| S:786 E:794 ||| JJ
susceptibility  ||| S:794 E:809 ||| NN
to  ||| S:809 E:812 ||| TO
vancomycin ||| S:812 E:822 ||| VB
.  ||| S:822 E:824 ||| .
Daptomycin  ||| S:824 E:835 ||| NNP
shows  ||| S:835 E:841 ||| VBZ
a  ||| S:841 E:843 ||| DT
good  ||| S:843 E:848 ||| JJ
therapeutic  ||| S:848 E:860 ||| JJ
efficacy  ||| S:860 E:869 ||| NN
in  ||| S:869 E:872 ||| IN
staphylococcal  ||| S:872 E:887 ||| JJ
endocarditis ||| S:887 E:899 ||| NN
:  ||| S:899 E:901 ||| :
MRSA  ||| S:901 E:906 ||| NNP
71 ||| S:906 E:908 ||| CD
% ||| S:908 E:909 ||| NN
,  ||| S:909 E:911 ||| ,
MSSA  ||| S:911 E:916 ||| NNP
75 ||| S:916 E:918 ||| CD
% ||| S:918 E:919 ||| NN
.  ||| S:919 E:921 ||| .
These  ||| S:921 E:927 ||| DT
data  ||| S:927 E:932 ||| NNS
suggest  ||| S:932 E:940 ||| VBP
the  ||| S:940 E:944 ||| DT
use  ||| S:944 E:948 ||| NN
of  ||| S:948 E:951 ||| IN
daptomycin  ||| S:951 E:962 ||| NN
as  ||| S:962 E:965 ||| IN
initial  ||| S:965 E:973 ||| JJ
therapy  ||| S:973 E:981 ||| NN
for  ||| S:981 E:985 ||| IN
treatment  ||| S:985 E:995 ||| NN
of  ||| S:995 E:998 ||| IN
staphylococcal  ||| S:998 E:1013 ||| JJ
endocarditis ||| S:1013 E:1025 ||| NN
,  ||| S:1025 E:1027 ||| ,
independently  ||| S:1027 E:1041 ||| RB
from  ||| S:1041 E:1046 ||| IN
methcillin  ||| S:1046 E:1057 ||| JJ
susceptibility ||| S:1057 E:1071 ||| NN
.  ||| S:1071 E:1073 ||| .
Some  ||| S:1073 E:1078 ||| DT
experimental  ||| S:1078 E:1091 ||| JJ
data  ||| S:1091 E:1096 ||| NNS
showed  ||| S:1096 E:1103 ||| VBD
that  ||| S:1103 E:1108 ||| DT
daptomycin  ||| S:1108 E:1119 ||| JJ
efficacy  ||| S:1119 E:1128 ||| NN
can  ||| S:1128 E:1132 ||| MD
diminish ||| S:1132 E:1140 ||| VB
,  ||| S:1140 E:1142 ||| ,
if  ||| S:1142 E:1145 ||| IN
it  ||| S:1145 E:1148 ||| PRP
is  ||| S:1148 E:1151 ||| VBZ
used  ||| S:1151 E:1156 ||| VBN
as  ||| S:1156 E:1159 ||| IN
a  ||| S:1159 E:1161 ||| DT
rescue  ||| S:1161 E:1168 ||| NN
therapy  ||| S:1168 E:1176 ||| NN
after  ||| S:1176 E:1182 ||| IN
vancomycin  ||| S:1182 E:1193 ||| JJ
failure ||| S:1193 E:1200 ||| NN
.  ||| S:1200 E:1202 ||| .
The  ||| S:1202 E:1206 ||| DT
thickness  ||| S:1206 E:1216 ||| NN
of  ||| S:1216 E:1219 ||| IN
bacterial  ||| S:1219 E:1229 ||| JJ
cell-wall  ||| S:1229 E:1239 ||| NN
recognized  ||| S:1239 E:1250 ||| VBN
in  ||| S:1250 E:1253 ||| IN
h-VISA  ||| S:1253 E:1260 ||| JJ
strains  ||| S:1260 E:1268 ||| NNS
can  ||| S:1268 E:1272 ||| MD
represent  ||| S:1272 E:1282 ||| VB
a  ||| S:1282 E:1284 ||| DT
physical  ||| S:1284 E:1293 ||| JJ
and  ||| S:1293 E:1297 ||| CC
electrical  ||| S:1297 E:1308 ||| JJ
barrier  ||| S:1308 E:1316 ||| NN
to  ||| S:1316 E:1319 ||| TO
reach  ||| S:1319 E:1325 ||| VB
both  ||| S:1325 E:1330 ||| PDT
the  ||| S:1330 E:1334 ||| DT
vancomycin  ||| S:1334 E:1345 ||| NN
and  ||| S:1345 E:1349 ||| CC
daptomycin  ||| S:1349 E:1360 ||| JJ
target  ||| S:1360 E:1367 ||| NN
site ||| S:1367 E:1371 ||| NN
.  ||| S:1371 E:1373 ||| .
However ||| S:1373 E:1380 ||| RB
,  ||| S:1380 E:1382 ||| ,
the  ||| S:1382 E:1386 ||| DT
reduced  ||| S:1386 E:1394 ||| JJ
efficacy  ||| S:1394 E:1403 ||| NN
of  ||| S:1403 E:1406 ||| IN
daptomycin  ||| S:1406 E:1417 ||| NNS
following  ||| S:1417 E:1427 ||| VBG
vancomycin  ||| S:1427 E:1438 ||| JJ
exposure  ||| S:1438 E:1447 ||| NN
is  ||| S:1447 E:1450 ||| VBZ
an  ||| S:1450 E:1453 ||| DT
extremely  ||| S:1453 E:1463 ||| RB
rare  ||| S:1463 E:1468 ||| JJ
event  ||| S:1468 E:1474 ||| NN
in  ||| S:1474 E:1477 ||| IN
the  ||| S:1477 E:1481 ||| DT
clinical  ||| S:1481 E:1490 ||| JJ
practice ||| S:1490 E:1498 ||| NN
.  ||| S:1498 E:1500 ||| .
It  ||| S:1500 E:1503 ||| PRP
is  ||| S:1503 E:1506 ||| VBZ
preferrable  ||| S:1506 E:1518 ||| VBN
to  ||| S:1518 E:1521 ||| TO
use  ||| S:1521 E:1525 ||| VB
daptomycin  ||| S:1525 E:1536 ||| VBN
as  ||| S:1536 E:1539 ||| IN
first  ||| S:1539 E:1545 ||| JJ
line  ||| S:1545 E:1550 ||| NN
therapy ||| S:1550 E:1557 ||| NN
,  ||| S:1557 E:1559 ||| ,
at  ||| S:1559 E:1562 ||| IN
a  ||| S:1562 E:1564 ||| DT
proper  ||| S:1564 E:1571 ||| JJ
dosage ||| S:1571 E:1577 ||| NN
.  ||| S:1577 E:1579 ||| .
As  ||| S:1579 E:1582 ||| RB
far  ||| S:1582 E:1586 ||| RB
as  ||| S:1586 E:1589 ||| IN
endocarditis  ||| S:1589 E:1602 ||| NN
is  ||| S:1602 E:1605 ||| VBZ
concerned ||| S:1605 E:1614 ||| VBN
,  ||| S:1614 E:1616 ||| ,
recent  ||| S:1616 E:1623 ||| JJ
data  ||| S:1623 E:1628 ||| NNS
proved  ||| S:1628 E:1635 ||| VBD
the  ||| S:1635 E:1639 ||| DT
excellent  ||| S:1639 E:1649 ||| JJ
daptomycin  ||| S:1649 E:1660 ||| JJ
tolerability ||| S:1660 E:1672 ||| NN
,  ||| S:1672 E:1674 ||| ,
with  ||| S:1674 E:1679 ||| IN
dosages  ||| S:1679 E:1687 ||| VBG
up  ||| S:1687 E:1690 ||| RP
to  ||| S:1690 E:1693 ||| TO
8-10  ||| S:1693 E:1698 ||| FW
mg ||| S:1698 E:1700 ||| FW
/ ||| S:1700 E:1701 ||| FW
kg ||| S:1701 E:1703 ||| FW
/ ||| S:1703 E:1704 ||| FW
die ||| S:1704 E:1707 ||| FW
.  ||| S:1707 E:1709 ||| .
During  ||| S:1709 E:1716 ||| IN
the  ||| S:1716 E:1720 ||| DT
treatment ||| S:1720 E:1729 ||| NN
,  ||| S:1729 E:1731 ||| ,
CPK  ||| S:1731 E:1735 ||| NNP
values  ||| S:1735 E:1742 ||| NNS
must  ||| S:1742 E:1747 ||| MD
be  ||| S:1747 E:1750 ||| VB
always  ||| S:1750 E:1757 ||| RB
monitored ||| S:1757 E:1766 ||| VBN
.  ||| S:1766 E:1768 ||| .
For  ||| S:1768 E:1772 ||| IN
endocarditis  ||| S:1772 E:1785 ||| VBG
sustained  ||| S:1785 E:1795 ||| VBN
by  ||| S:1795 E:1798 ||| IN
vancomycin-resistant  ||| S:1798 E:1819 ||| JJ
enterococci ||| S:1819 E:1830 ||| NN
,  ||| S:1830 E:1832 ||| ,
therapeutic  ||| S:1832 E:1844 ||| JJ
choices  ||| S:1844 E:1852 ||| NNS
are  ||| S:1852 E:1856 ||| VBP
based  ||| S:1856 E:1862 ||| VBN
on  ||| S:1862 E:1865 ||| IN
linezolid  ||| S:1865 E:1875 ||| NN
or  ||| S:1875 E:1878 ||| CC
ampicillin-ceftriaxone  ||| S:1878 E:1901 ||| JJ
combination  ||| S:1901 E:1913 ||| NN
therapy ||| S:1913 E:1920 ||| NN
.  ||| S:1920 E:1922 ||| .
Daptomycin  ||| S:1922 E:1933 ||| NNP
alone ||| S:1933 E:1938 ||| RB
,  ||| S:1938 E:1940 ||| ,
or  ||| S:1940 E:1943 ||| CC
in  ||| S:1943 E:1946 ||| IN
association  ||| S:1946 E:1958 ||| NN
with  ||| S:1958 E:1963 ||| IN
gentamycin  ||| S:1963 E:1974 ||| NN
and  ||| S:1974 E:1978 ||| CC
rifampin ||| S:1978 E:1986 ||| NN
,  ||| S:1986 E:1988 ||| ,
can  ||| S:1988 E:1992 ||| MD
represent  ||| S:1992 E:2002 ||| VB
a  ||| S:2002 E:2004 ||| DT
promising  ||| S:2004 E:2014 ||| JJ
therapeutic  ||| S:2014 E:2026 ||| JJ
alternative ||| S:2026 E:2037 ||| NN
.  ||| S:2037 E:2039 ||| .
